Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2026)

Amylyx Pharmaceuticals' Accounts Payables history runs 6 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 26.63% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 26.63% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, up 19.73% from the prior year.
• Accounts Payables was little changed at $3.5 million in Q1 2026 per AMLX's latest filing, from $3.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $24.7 million in Q2 2023 and bottomed at $1.5 million in Q3 2024.
• The 5-year median for Accounts Payables is $6.3 million (2022), against an average of $8.6 million.
• Across the five-year window, Accounts Payables slumped 86.68% in 2024 and soared 259.05% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then slumped by 86.68% to $2.9 million in 2024, then gained by 19.73% to $3.5 million in 2025, then advanced by 0.28% to $3.5 million in 2026.
• Per Business Quant, the three latest AMLX Accounts Payables figures stand at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $5.3 million (Q3 2025).